Recent studies proved that targeting ANXA1 abrogated Treg-mediated immune suppression in triple-negative breast cancer, and ANXA1 was considered a worse prognostic and TME marker in gliomas (Bai et al., 2020; Lin et al., 2021). This evidence concerns the gene ANXA1 and central nervous system cancer.